You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
Mallinckrodt
McKinsey
Merck

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 10,472,424

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,472,424
Title:Treatment with anti-PCSK9 antibodies
Abstract: The present invention relates to therapeutic dosing regimens utilizing a dose reduction strategy for treating disorders characterized by marked elevations of low density protein cholesterol (LDL-C) in the plasma of a patient. The subject therapeutic dosing regimens involve delivering as a single administration or plurality of administrations of an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody as an initial dose of at least about 100 mg, and delivering as a single administration or plurality of administrations at a subsequent dose in an amount that is about the same as the initial dose, or at least half the initial dose after the patient has a LDL-C level at or below about 25, 20, 15 or 10 mg/dL, preferably at or below 10 mg/dL.
Inventor(s): Cropp; Anne Barbara (Madison, CT), Kim; Albert (Newton, MA), Plowchalk; David Raymond (Waterford, CT), Sweeney; Kevin Richard (East Lyme, CT), Wang; Ellen Qiao (Brooklyn, NY)
Assignee: Pfizer Inc. (New York, NY)
Application Number:15/510,600
Patent Claims:see list of patent claims

Details for Patent 10,472,424

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Pfizer Inc. (New York, NY) 2034-09-23 RX Orphan search
Sanofi Aventis PRALUENT alirocumab INJECTABLE;INJECTION 125559 001 2017-04-24   Start Trial Pfizer Inc. (New York, NY) 2034-09-23 RX search
Sanofi Aventis PRALUENT alirocumab INJECTABLE;INJECTION 125559 002 2017-04-24   Start Trial Pfizer Inc. (New York, NY) 2034-09-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKesson
Boehringer Ingelheim
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.